Alphanine Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to high bleeding risk in hemophilia b, limited early treatment options, reliance on plasma derived factor ix, growth of hemophilia clinics, improved diagnostic capabilities.

The growth in the forecast period can be attributed to expansion of prophylactic treatment protocols, increased patient life expectancy, growth of home care infusion services, rising awareness of hemophilia management, improved reimbursement coverage. Major trends in the forecast period include rising demand for factor ix replacement, expansion of prophylactic hemophilia b therapy, increased use in surgical and trauma care, growing adoption of home infusion programs, strengthening of specialty treatment networks.

The rising prevalence of hemophilia is expected to drive the growth of the alphanine market in the coming years. Hemophilia is a rare, inherited bleeding disorder in which the blood fails to clot properly due to the absence or deficiency of specific clotting factors, namely factors VIII and IX. The increase in hemophilia prevalence is attributed to factors such as improved diagnosis and awareness, enhanced reporting and data collection, and genetic inheritance patterns. Alphanine supports the treatment of hemophilia by supplying clotting factor VIII, which is crucial for controlling bleeding and preventing hemorrhagic events in individuals with hemophilia A. For instance, in July 2025, according to the National Blood Authority, an Australia-based blood management agency, there were 2,788 patients living with hereditary haemophilia A (HMA) in 2023-2024, an increase from 2,681 patients in 2022-2023. Therefore, the increasing prevalence of hemophilia is fueling the growth of the alphanine market.

The growth of the aging population is expected to contribute to the expansion of the alphanine market going forward. An aging population refers to a demographic shift in which the share of elderly individuals, typically those aged 65 years and above, rises relative to other age groups. This trend is driven by improvements in healthcare, enhanced living standards, and advancements in medical technology, which have resulted in longer life expectancy and declining birth rates. Alphanine is used among the aging population to manage hemophilia and other bleeding disorders by providing clotting factor replacement therapy to prevent or control bleeding episodes. For instance, in July 2024, according to the House of Commons Library, the UK-based library and information resource of the lower house of the British Parliament, individuals aged 65 and above represented approximately 19% of the UK population in 2022, totaling around 12.7 million people. By 2072, this segment is projected to reach 22.1 million, accounting for 27% of the population. Therefore, the expansion of the aging population is driving the growth of the alphanine market.

The growing awareness of rare diseases is expected to support the growth of the alphanine market in the coming years. Rare diseases are conditions that affect a small proportion of the population and often pose challenges related to diagnosis, treatment, and access to healthcare due to their low prevalence. Increased awareness of rare diseases is fueled by greater media attention, advocacy initiatives, and advancements in diagnostic technologies, which improve early detection and access to specialized therapies for affected individuals. Alphanine contributes to the rising awareness of rare diseases by providing a targeted treatment for hemophilia, a rare bleeding disorder, thereby highlighting both the condition and the need for effective therapeutic options. For instance, in February 2024, according to the Personalized Medicine Coalition, a US-based nonprofit organization, the USFDA approved 16 new personalized treatments for rare disease patients in 2023, a notable increase from 6 personalized treatments in 2022. Therefore, the increasing awareness of rare diseases is driving the alphanine market.

Major companies operating in the alphanine market are Grifols Biologicals Inc.

North America was the largest region in the alphanine market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the alphanine market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the alphanine market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs have impacted the alphanine market by increasing costs related to plasma collection, fractionation processes, and cold chain logistics. These impacts have influenced treatment affordability in hospital and clinic settings, particularly in regions dependent on imported plasma products. Asia pacific and africa experience higher cost sensitivity due to supply constraints. However, tariffs have supported domestic plasma programs, encouraged regional manufacturing, and strengthened long term treatment availability.

The alphanine market research report is one of a series of new reports that provides alphanine market statistics, including alphanine industry global market size, regional shares, competitors with a alphanine market share, detailed alphanine market segments, market trends and opportunities, and any further data you may need to thrive in the alphanine industry. This alphanine market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Alphanine is a clotting factor concentrate primarily used in the treatment of hemophilia B, a bleeding disorder resulting from a deficiency of factor IX. It is a plasma-derived product that helps control and prevent bleeding episodes by restoring the missing clotting factor in patients with hemophilia B and is a highly purified, plasma-derived coagulation factor IX (FIX) concentrate indicated for managing the condition.

The primary formulations available in the alphanine market include lyophilized powder and intravenous solutions. Lyophilized powder refers to a medication that has been freeze-dried to eliminate moisture, enabling extended shelf life and convenient storage. The therapy is indicated for various conditions such as hemophilia A, hemophilia B, and hemophilia C and is used across multiple patient groups, including pediatric, adult, and geriatric populations. Distribution channels include hospitals, specialty clinics, retail pharmacies, and mail-order pharmacies.

The alphanine market consists of sales of Factor IX concentrates, gene therapy solutions, and treatment regimens. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.